Zygomycosis - Current epidemiological aspects

Mycoses

Volumn 50, Issue SUPPL. 1, 2007, Pages 50-55

  Glöckner, Andreas ^a   Vehreschild, Jörg J ^b   Cornely, Oliver A ^b  

^a Neurologisches Rehabilitationszentrum Greifswald   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Allogeneic stem cell transplantation; Aspergillosis; High dose chemotherapy; Leukaemia; Zygomycosis

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MUCORMYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DIAGNOSIS, DIFFERENTIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; ZYGOMYCOSIS;

EID: 33947707198     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01380.x     Document Type: Article

References (32)

1. Spira A, Brecher S, Karlinsky J. Pulmonary mucormycosis in the setting of chronic obstructive pulmonary disease. A case report and review of the literature. Respiration 2002; 69: 560-3.
2. Jamadar DA, Kazerooni EA, Daly BD, White CS, Gross BH. Pulmonary zygomycosis: CT appearance. J Comput Assist Tomogr 1995; 19: 733-8.
3. Pinto PS. The CT Halo Sign. Radiology 2004; 230: 109-10.
4. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-66.
5. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-29.
6. Ribes J, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microb Rev 2000; 13: 236-301.
7. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000; 30: 851-6.
8. Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001; 44: 253-60.
9. Kontoyiannis DP, Lionakis MS, Lewis RE et al.. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
10. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-46.
11. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588-90.
12. Marty FM, Lee SJ, Fahey MM et al.. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102: 2768-76.
13. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al.. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584-7.
14. Vigouroux S, Morin O, Moreau P et al.. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: e35-7.
15. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
16. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
17. Roden MM, Zaoutis TE, Buchanan WL et al.. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
18. Pappas PG, Alexander B, Marr K, Kontoyiannis DP et al. Invasive Fungal Infections (IFIs) in Hematopoietic Stem Cell (HSCTs) and Organ Transplant Recipients (OTRs): Overview of the TRANSNET Database. IDSA, 2004, Abstract 671.
19. Rickerts V, Böhme A, Just-Nübling G. Risikofaktoren für invasive Zygomykosen bei Patienten mit hämatologischen Neoplasien. Mycoses 2002; 45 (Suppl. 1): 27-30.
20. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-2.
21. Nucci M. Emerging moulds: fusarium, scedosporium and zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16: 607-12.
22. Fukuda T, Boeckh M, Carter RA et al.. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-33.
23. Marr KA. Non-Myeloablative Transplantation: What are the Problems? ICAAC, 2004, Präsentation 1048.
24. Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005; 17: 89-92.
25. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-51.
26. Vogelsang GB. Chronic graft versus host disease (cGVHD)is more frequent due to changes in the practice of stem cell transplantation. Blood 2003; 102: 1149-50.
27. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
28. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
29. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101: 3365-72.
30. Marr KA, Crippa F, Leisenring Wet al.. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-33.
31. Winston DJ, Maziarz RT, Chandrasekar PH et al.. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-13.
32. Herbrecht R, Denning DW, Patterson TF et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.